What's new on Contemporary Pediatrics: October 19 to October 23

Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

Some staffing problems stabilize with financial incentives, and technology helps, but an AMGA report shows predictions for this year hold true.

A recent study looked at how patients with type 1 diabetes used telehealth during the pandemic, and how it has influenced their preferred method of health care.